Lilly buys AtaiBeckley for $2.8B upfront to challenge J&J for psychedelic mental health market (July 16, 2026 ) by Nick Paul Taylor Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a psychedelic mental health sector targeted by companies including Johnson & Johnson. AtaiBeckley’s lead candidate is BPL-003, a

Kalohexis is working on peptide therapies, including one for obesity that could offer an alternative approach to the GLP-1s that currently dominate the weight loss space. (July 8, 2026 ) by Tristan Manalac Kalohexis is working on peptide therapies, including one for obesity that could offer an alternative approach to the GLP-1s that currently dominate the weight loss space. Kalohexis,